• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Tumor primary site may be a prognostic factor for patients with Merkel cell carcinoma

byTeddy Guo
September 15, 2021
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click to read the study in the Journal of the American Academy of Dermatology. 

RELATED REPORTS

Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

Use of certain biologics or disease modifying antirheumatic drugs may be associated with cancer risk

Tags: dermatologyMerkel Cell CarcinomaMerkel cell carcinoma (MCC)Primary tumor siteskin cancerskin cancer survivalTumor site
Previous Post

#VisualAbstract: Half of patients hospitalized with COVID-19 continue to have symptoms after 1 year

Next Post

In-school transmission of COVID-19 limited even during wide community spread

RelatedReports

Rapid growth of medical artificial intelligence technology usage identified from insurance claims analysis, yet major barriers to widespread adoption remain
Chronic Disease

Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines

March 13, 2025
Increased risk of subsequent melanoma after first melanoma diagnosis
Dermatology

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

December 12, 2024
No difference in PET-CT surveillance versus planned neck dissection in advanced head and neck cancer
Chronic Disease

Use of certain biologics or disease modifying antirheumatic drugs may be associated with cancer risk

November 30, 2024
Medicare beneficiaries have a lower rate of delayed melanoma surgeries
Chronic Disease

Adjuvant dabrafenib and trametinib improve survival in stage III melanoma

November 25, 2024
Next Post
Novel coronavirus identified from patients with pneumonia in Wuhan, China

In-school transmission of COVID-19 limited even during wide community spread

“No Evidence of Disease Activity” may be useful goal in multiple sclerosis

Metagenomic next-generation sequencing of cerebrospinal fluid yielded improved sensitivity and specificity for the detection of central nervous system neoplasms

Compliance-linked incentives increase infant immunizations rates in rural India

Heterologous ChAdOx1 prime-boosted vaccination schedules are non-inferior to homologous vaccination

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women
  • GSK and Hengrui Pharma Forge $500 Million China Collaboration
  • #VisualAbstract: Ciprofloxacin is Noninferior to Aminoglycoside–Ciprofloxacin for Treatment of Bubonic Plague
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.